Nurix Therapeutics, Inc. maintains an operating account at Silicon Valley Bank (SVB) with a cash balance of less than 1% of the company's total cash, cash equivalents, and marketable securities, and believes its exposure to loss as a result of SVB's receivership is immaterial.